We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+30.52%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.74B
AUM Growth
+$261M
Cap. Flow
-$140M
Cap. Flow %
-5.1%
Top 10 Hldgs %
32.74%
Holding
95
New
12
Increased
24
Reduced
31
Closed
21

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$88.4M
2
UTHR icon
United Therapeutics
UTHR
+$54.7M
3
CVS icon
CVS Health
CVS
+$52.7M
4
AVTR icon
Avantor
AVTR
+$43.5M
5
ABBV icon
AbbVie
ABBV
+$41.5M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$60.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$54.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$44.3M
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$42.1M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$38.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATEC icon
76
Alphatec Holdings
ATEC
$1.48B
– –
-309,400
Closed -$4.01M
BIIB icon
77
Biogen
BIIB
$30.9B
– –
-115,400
Closed -$29.7M
CI icon
78
Cigna
CI
$78.4B
– –
-207,700
Closed -$60.7M
CVAC
79
DELISTED
CureVac
CVAC
– –
-3,116,100
Closed -$21.3M
DXCM icon
80
DexCom
DXCM
$29B
– –
-377,700
Closed -$35.2M
HCA icon
81
HCA Healthcare
HCA
$90.6B
– –
-114,800
Closed -$28.2M
MLTX icon
82
MoonLake Immunotherapeutics
MLTX
$1.56B
– –
-777,172
Closed -$44.3M
PACB icon
83
Pacific Biosciences
PACB
$435M
– –
-1,034,294
Closed -$8.64M
PRTA icon
84
Prothena Corp
PRTA
$448M
– –
-382,305
Closed -$18.4M
ROIV icon
85
Roivant Sciences
ROIV
$23.6B
– –
-1,503,302
Closed -$17.6M
SDGR icon
86
Schrodinger
SDGR
$1.13B
– –
-399,000
Closed -$11.3M
SRPT icon
87
Sarepta Therapeutics
SRPT
$1.64B
– –
-450,000
Closed -$54.5M
UHS icon
88
Universal Health Services
UHS
$10.2B
– –
-182,000
Closed -$22.9M
VERV
89
DELISTED
Verve Therapeutics
VERV
– –
-285,334
Closed -$3.78M
VTYX
90
DELISTED
Ventyx Biosciences
VTYX
– –
-354,900
Closed -$12.3M
ZNTL icon
91
Zentalis Pharmaceuticals
ZNTL
$332M
– –
-2,100,000
Closed -$42.1M
GRTS
92
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-2,733,800
Closed -$4.7M
ALPN
93
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-657,280
Closed -$7.53M
RYZB
94
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-500,000
Closed -$11.1M
NSTG
95
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-2,299,100
Closed -$3.95M
1 2 3
4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2023 Portfolio in Review

As of Q4 2023, Avidity Partners Management held 95 positions worth $2.74B, up 11% from $2.48B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $140M in Q4 2023, closing 21 positions and reducing 31 holdings. Its most notable exit was Cigna, an estimated $60.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Thermo Fisher Scientific worth $96.9M.

  • Avidity Partners Management's largest Q4 2023 buy was Thermo Fisher Scientific: 182,600 shares worth $96.9M.
  • Avidity Partners Management added most to Structure Therapeutics in Q4 2023, an estimated $33.2M increase.
  • Avidity Partners Management's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $38.5M.
  • Avidity Partners Management fully exited Cigna in Q4 2023, selling an estimated $60.7M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.74B portfolio in Q4 2023.
  • Avidity Partners Management opened 12 new positions and closed 21 in Q4 2023.
  • Avidity Partners Management's portfolio value rose 11% quarter-over-quarter to $2.74B.

Based on Avidity Partners Management's 13F filing for Q4 2023, filed 14 Feb 2024.